A revenue-generating, small-cap Canadian pharmaceutical company

Revenue Projected at $150,000,000 by 2025

Valeo Pharma Inc. Profile

Valeo Pharma: A Successful, Revenue-Generating, Small-Cap Canadian Pharmaceutical Company 

What Makes Valeo Pharma Such An Interesting Pharmaceutical Company?


  • Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®, three transformational products launched during 2021, will help accelerate revenues and margins in 2022
  • Public reimbursement secured in most provinces in Canada for Redesca, Enerzair Breezhaler and Atectura Breezhaler and all major private insurers
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • Hesperco™ Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial
  • Completion of new corporate structure to allow for significant growth over the coming years and enable accelerated growth of commercial activities
  • $43 million raised in financings throughout 2021 and subsequent to year-end


Commercial Products



What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization


Here’s just a few products already approved:


Launch: Q1-2021

Status: Approved by Health Canada December 2020

Indication: Injectable blood thinner

Market size:  $200M

Received positive recommendation for public reimbursement in Quebec

To be covered under Ontario Public Drug Benefit program

Peak sales estimate $30 - $40M, sales margin 55 - 60%


Launch: Launched in Q4 -2020

Status: Approved by Health Canada

What is it: Anti-Oxidant - Immune system support

How’s it sold: Retail, Online (www.hesperco.com, www.amazon.ca)

Market Size: $500M

  • Available in approximately 300 stores under the Loblaws banners
  • Clinical study yields encouraging results that hesperidin may help reduce COVID-19 associated symptoms





Launch: Q3 2019

Status: Received positive recommendation for public reimbursement in Quebec

Use: Parkinson's disease, 1st treatment launched in Canada since 2006

Patient base: 100,000 in Canada 2nd chronic neurodegenerative disorder after Alzheimer

Market Size: $20M

%Peak sales estimate $8M, sales margin 65-70 %



The Valeo ModelThe-Model

Company Forecast

  • All portfolio & pipeline products to be on the market by end of 2022
  • Solid pipeline composed of “licensed” products
  • Peak Sales reached 2-4 years after the market launch
  • From 1 product on the market to 12 in 4 years and more to come
  • The forecast excludes any new product licensing.


Recent Releases


Last changed at 27-Mar-2023 10:33AM by AGORACOM